ClinicalTrials.gg
RecruitingNCT05131685DRIFTUpdated Jul 1, 2026

Distal Radius Interventions for Fracture Treatment

An interventional study of Reduction and Immobilization in Fracture Distal Radius, sponsored by Ann & Robert H Lurie Children's Hospital of Chicago. Recruiting at 24 sites in United States. Open to participants aged 4 Years to 10 Years. Per ClinicalTrials.gov, last updated 2026-07-01.

Sponsored by Ann & Robert H Lurie Children's Hospital of Chicago · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2023; still recruiting 3 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
334
Allocation
Randomized
Ages
4 Years to 10 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 72 studies in Wrist Fractures with a site in United States — 12 open to participants now, 19 under way, 1 of them phase 3. Wrist Fractures · United States.

Planned enrollment
3rd of 64
334 · median 52
Started
2023
with 5 others
No phase
48 of 72
8 open now
Primary completion
2030-12
later than 18 of 18 live
Registered
48th of 72
by date

Among the 72 studies in Wrist Fractures with a site in United States, this one is the 3rd largest by planned enrollment of the 64 interventional ones that give a count, is one of 6 that started in 2023, is one of 48 with no phase, reaches primary completion later than 18 of the 18 other live ones, and was the 48th registered.

Wrist Fractures

331 studies on the registry are indexed under Wrist Fractures; 71 are open to participants now.

Browse Wrist Fractures studies →

Open to participants now

12 of the 72 studies in Wrist Fractures with a site in United States are open now. Recruiting first, the newest first:

6 more — sign in →

All 12 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 41 Wrist Fractures studies recruiting now, 20 (49%) set no upper age limit and 13 (32%) stop at 75 or younger; 7 take children under 18; 6 take healthy volunteers.

This study: 4 Years to 10 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 72 studies in Wrist Fractures with a site in United States, or all of them as a file.
02

Study summary

This protocol describes a multicenter, prospective randomized superiority trial with a patient preference cohort comparing functional outcomes between children treated with sedated reduction versus no formal reduction.

Read the detailed description

INTRODUCTION

Distal radius fractures (DRFs) make up 20-25% of all pediatric fractures (Brudvik 2003, Cooper 2004), and are the most common fractures seen in the emergency department in children in the United States. (Naranje 2016)

The available evidence on distal radius fracture (DRF) reduction/non-reduction is based on case series, observational comparisons, and expert opinions. Displaced metaphyseal distal radius fracture (DRFs) have historically been treated with attempts at closed reduction (under conscious sedation or anesthesia). This approach was supported by retrospective studies and consensus opinion that anatomical alignment was necessary for normal function.(Rockwood 2010 text, Bae 2012 JPO) Furthermore, it is unsettling for physicians and families to see bones overlapped on a radiograph when a straightening procedure can be completed in a straightforward fashion. However, simple immobilization without attempted reduction has recently been reported for management of DRFs in children under age 10.(Crawford 2012) This approach is conceptually supported by the fracture's proximity to the distal radial physis and the remaining growth of the child, which provides significant remodeling potential and can allow for improvement of malalignment as the child grows.(Crawford 2010 JBJSAm, Price 1990 JPO) There is a paucity of literature comparing reduced to non-reduced fractures to guide management. No established or standardized guidelines exist for the optimal management of completely displaced fractures. Surveys have identified widely discrepant recommendations and high practice variation for treatments for identical DRF patterns.(Georgiadis 2019 POSNA or JPO 2020) Although these studies provide preliminary data to support clinical management, the studies lack a control population for comparison, are retrospective, lack randomization, have variable follow-up times and have no standard definitions of outcomes. In addition, the studies used radiographic or non-validated outcome measures to make conclusions, limiting their utility in identifying optimal management.

It appears that children may be undergoing unnecessary procedures, sedations, and anesthetics. The use of anesthesia and sedation has recently come into question as studies examine their effects on cognitive development. (Loepke 2013, Flick 2011) There could be a significant cost savings in terms of procedure costs, hospital costs, and lost time from work if non-procedure management is found to be a non-inferior treatment regimen. The physician investigators want to tell patients that they know why they are proposing treatments, the risks and benefits of the treatment, and use evidence to inform these recommendations and the family's decisions. The proposed trial will compare the effectiveness of alignment under sedation/anesthesia with simple immobilization for management of displaced DRFs in children, providing critical data regarding optimal management of this common fracture. Therefore, this study's primary question is: does anatomic reduction under sedation/anesthesia of DRF result in improved patient outcomes at six months compared to immobilization without attempted reduction?

Multiple reasons exist for comparing these treatment strategies for DRF, including: 1) these are the most common treatments for DRF, 2) the strategies are widely divergent (operative vs. non-operative), and 3) there is a large potential to change clinical practice.

QUALITY ASSURANCE AND QUALITY CONTROL

Quality control (QC) procedures will be implemented beginning with the data entry system and data QC checks that will be run on the database will be generated. Any missing data or data anomalies will be communicated to the site(s) for clarification/resolution.

Following written Standard Operating Procedures (SOPs), the monitors will verify that the clinical trial is conducted and data are generated and biological specimens are collected, documented (recorded), and reported in compliance with the protocol, International Conference on Harmonisation Good Clinical Practice (ICH GCP), and applicable regulatory requirements (e.g., Good Laboratory Practices (GLP), Good Manufacturing Practices (GMP)).

The investigational site will provide direct access to all trial related sites, source data/documents, and reports for the purpose of monitoring and auditing by the sponsor, and inspection by local and regulatory authorities.

For specific details regarding quality assurance and quality control, please see the data management plan.

DATA HANDLING AND RECORD KEEPING

DATA COLLECTION AND MANAGEMENT RESPONSIBILITIES

Data collection is the responsibility of the clinical trial staff at the site under the supervision of the site investigator. The investigator is responsible for ensuring the accuracy, completeness, legibility, and timeliness of the data reported.

Clinical data and patient reported outcomes will be entered into REDCap, a 21 CFR Part 11-compliant data capture system provided by the DCRI. The data system includes password protection and internal quality checks, such as automatic range checks, to identify data that appear inconsistent, incomplete, or inaccurate. Clinical data will be entered directly from the source documents.

SAFETY OVERSIGHT

Safety oversight will be under the direction of a Data and Safety Monitoring Board (DSMB) composed of individuals with the appropriate expertise and knowledge of pediatric orthopaedic surgery usually obtained via an accredited pediatric orthopaedic fellowship. Members of the DSMB should be independent from the study conduct and free of conflict of interest, or measures should be in place to minimize perceived conflict of interest. The DSMB will meet at least semiannually to assess safety data on each arm of the study. The DMSB will operate under the rules of an approved charter that will be written and reviewed at the organizational meeting of the DSMB. At this time, each data element that the DSMB needs to assess will be clearly defined. The DSMB will provide its input to NIAMS.

Statistical Hypotheses:

  • Primary Efficacy Endpoint(s):

The null hypothesis is that there is no difference in PROMIS UE (CAT) at 1 year between arms. The alternative hypothesis is that there is a difference between arms.

SAMPLE SIZE DETERMINATION

Sample size calculations were based on detecting a clinically meaningful difference in the Patient Reported Outcomes Measurement Information System (PROMIS) Upper extremity computer adaptive test (CAT) of 4 points. PROMIS measures use a T-score metric with a mean of 50 and standard deviation of 10 in a reference population. A sample size of 133 per am, assuming a two-sided type I error rate of 0.05, will provide 90% power to detect a difference between arms of 4 points.

To conservatively account for 20% lost-to-follow-up or missing data on the primary outcome at 12 months, the investigators have inflated the sample size to 167 per arm, for a total target enrollment of 334.

A blinded sample size re-estimation based on the standard deviation of the primary outcome, after 100 participants have completed the 6 month follow-up, will be performed.

GENERAL APPROACH

Note: Statistical Analyses are described in depth in the Statistical Analysis Plan.

Descriptive statistics will summarize all baseline variables by arm. Specifically, continuous variables will be summarized using mean and standard deviation, for normally distributed variables, and median and IQR, for non-normally distributed variables. Categorical variables will be summarized with frequency and percentages. There will be no formal hypothesis testing for comparison of baseline characteristics between treatment arms.

Primary analyses of the primary outcome at 1 year will be assessed with a two-sided type I error rate of 0.05 for a MCID of 4 points. A false discovery rate (FDR) correction will be applied to analyses of all secondary outcomes to account for multiplicity.

ANALYSIS OF THE PRIMARY EFFICACY ENDPOINT(S)

Analysis for the primary aim will utilize a mixed effect model for the primary outcome, PROMIS Upper Extremity Function at 12 months, with a fixed effect for treatment arm and a random effect for site. Fixed effects will also include all variables considered in the randomization (site, sex, age), to control for imbalances in both the design and analysis. Incorporation of a random center effect will allow for separation of between site and within site variance components. Distributional assumptions will be assessed and transformations or inclusions of higher order terms may be considered, as appropriate.

ANALYSIS OF THE SECONDARY ENDPOINT(S)

Secondary analyses will employ similar methods for all secondary continuous outcomes. A generalized linear mixed effect model with Poisson distribution and log link will be used for the secondary count outcome, number of revisions, refractures, re-reductions, and reoperations. Distributional assumptions will be assessed, and a dichotomous version may be used instead if appropriate (any revisions, refractures, reductions, and reoperations vs never). Descriptive statistics will be used summarize satisfaction survey by treatment arm. Simple non-parametric test statistics or chi-squared test statistics may be used to compare ordinal and binary variables, respectively.

Exploratory analyses may also consider trajectories of the primary outcome measured over time. Fixed effects for baseline PROMIS Upper Extremity Function, time, treatment arm, and the interaction will be included in a linear mixed effect model with random patient nested in center effects.

A False Discovery Rate (FDR) correction will be applied to all secondary analyses to account for multiplicity.

03

Conditions studied

  • Fracture Distal Radius

Browse trials for

04

Who can participate

Ages eligible
4 Years to 10 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Provision of signed and dated form by parent or legal guardian
  2. Stated willingness to comply with all study procedures and availability for the duration of the study
  3. Male or female, aged 4-10 years
  4. Diagnosis of 100% dorsally displaced radius metaphyseal fracture with any or no ulna involvement
  5. Fracture is less than 5cm from the distal radial growth plate
  6. Willing to adhere to the immobilization regimen
  7. Fracture is acute (occurred less than 10 days prior to consent and assignment of treatment arm AND with ability to be taken to operating room (OR) or reduced in the emergency department (ED)

Exclusion criteria

Exclusion Criteria:

  1. Physeal involvement of fracture
  2. Presence of open fracture, pathologic fracture, neuromuscular disease, or metabolic disease
  3. Fractures other than the ulna near the same level in the ipsilateral arm
  4. Fracture cannot be treated with acute reduction due to being older than 10 days
  5. Patient and parents are unable to adhere to procedures or complete follow-up due to insufficient comprehension of consent form or surveys or developmental delay
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
334 participants (estimated)

Study arms

  • Experimental
    Non-sedated Immobilization

    Immobilization in a cast without reduction

    Procedure: Immobilization

  • Active comparator
    Formal Reduction

    closed reduction under conscious sedation followed by casting

    Procedure: Reduction

Interventions

  • ProcedureReduction

    closed reduction under conscious sedation followed by casting

  • ProcedureImmobilization

    immobilization in cast without reduction

06

What researchers measure

Primary outcomes

  1. PROMIS Pediatric CAT V2.0 - Physical Function- Upper Extremity

    pediatric upper extremity function PROMIS computer adaptive test (PROMIS UE CAT)

    Time frame: 1 year follow-up

Secondary outcomes

  1. PROMIS Pediatric CAT v2.0 - Physical Function- Upper Extremity

    functional and patient reported outcomes

    Time frame: 6 weeks, 3 months, and 6 months

  2. Disabilities of the Arm, Shoulder and Hand (DASH) S/PA

    functional and patient reported outcomes

    Time frame: 6 weeks, 3 months, 6 months, and 1 year

  3. PROMIS Pediatric V2.0 - Pain interference

    functional and patient reported outcomes

    Time frame: 6 weeks, 3 months, and 1 year

  4. Wong-Baker FACES Pain score

    functional and patient reported outcomes

    Time frame: 6 weeks and 3 months

  5. PROMIS Pediatric V1.0- Global Health- Global Score

    functional and patient reported outcomes

    Time frame: 6 weeks, 3 months, 6 months, and 1 year

  6. PROMIS Pediatric V1.0 - Global Health- Fatigue Interference

    functional and patient reported outcomes

    Time frame: 6 weeks, 3 months, 6 months, and 1 year

  7. PROMIS Pediatric V1.0- Global Health - Pain Interference

    functional and patient reported outcomes

    Time frame: 6 weeks, 3 months, 6 months, and 1 year

  8. Number of revisions, refractures, re-reductions, and reoperations

    clinical outcomes

    Time frame: within 1 year

  9. Other complications

    functional and patient reported outcomes

    Time frame: 1 year

  10. Missed work or school

    functional and patient reported outcomes

    Time frame: 3 months

  11. Satisfaction questionnaire

    functional and patient reported outcomes

    Time frame: 3 months, 6 months, and 1 year

  12. Cosmesis

    functional and patient reported outcomes

    Time frame: 6 weeks, 3 months, 6 months, and 1 year

  13. Radiographic alignment

    functional and patient reported outcomes

    Time frame: 6 weeks

07

Study locations

24 of 24 sites recruiting
08

References and documents

Publications

  • Balmert Bonner L, Janicki J, Georgiadis A, Truong W, Harris Beauvais D, Belthur M, Daley EL, Franzone J, Howard A, May C, Rockhold F, Schulz J, Bailey M, Chiswell K, DeLaRosa J, Brooks JT, Cantanzano AA, Chan A, Chu A, Dodwell ER, El-Hawary R, Ellis H, Fitzgerald R, Frick S, Ganley TJ, Gargiulo D, Gauthier L, Gill CS, Goldstein R, Halsey MF, Hardesty C, Ho C, Kaushal N, Lawrence JT, Lee RJ, Leitch KK, Masrouha K, Mitchell S, OMalley N, Payares-Lizano M, Perry D, Ramalingam W, Rhodes J, Sanders J, Shah AS, Sharkey M, Silva M, Silva S, Thompson R, Vorhies J, Wright JG, Young C, Burgess J; IMPACCT Consortium. Distal Radius Interventions for Fracture Treatment (DRIFT) trial: study protocol for a multicentre randomised clinical trial of completely translated distal radius fractures at paediatric hospitals in North America. BMJ Open. 2025 Oct 29;15(10):e088273. doi: 10.1136/bmjopen-2024-088273. PubMed 41161832 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2023 (actual). Primary completion is estimated for Dec 2030, 92 months after the start.

Of 128 non-industry interventional studies with no phase under Wrist Fractures, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 50. This study's planned 92 months is above that.

Counting every sponsor, half of 129 studies reached it within 24 months; a quarter within 16 and three quarters within 50.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 4, 2021
First posted
Nov 23, 2021
StartActual
Apr 9, 2023
Primary completionEst.
Dec 31, 2030
CompletionEst.
Jul 31, 2031
Last update
Jul 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05131685
Responsible party
Joseph Janicki (Attending Surgeon, Ann & Robert H Lurie Children's Hospital of Chicago) — Principal investigator
First posted
Nov 23, 2021
Start date
Apr 9, 2023
Primary completion
Dec 31, 2030 (estimated)
Completion
Jul 31, 2031 (estimated)
Last update
Jul 1, 2026

Study contacts

Jamie Burgess, PhD
Contact
jburgess@luriechildrens.org
312-227-6531
Michelle Adzido, MA
Contact
madzido@luriechildrens.org
312-227-2492
Joseph Janicki, MD
principal investigator · Ann & Robert H Lurie Children's Hospital of Chicago

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion